Thryv Therapeutics synthesizes SGK1 inhibitors
AI Briefing
- Thryv Therapeutics Inc. announces new SGK1 inhibitors for atrial fibrillation, heart failure, and inflammatory disorders treatment.
- The inhibitors are crystalline forms of serum/glucocorticoid-regulated kinase 1 (SGK1) and maleic acid compounds.
- These compounds may be useful for treating various conditions, including atrial fibrillation and heart failure.
Context
Thryv Therapeutics Inc. has synthesized new crystalline forms of SGK1 inhibitors and maleic acid. These compounds may be useful for treating various conditions.
These new forms of SGK1 inhibitors and maleic acid could lead to treatments for atrial fibrillation, heart failure, and inflammatory disorders.
Advertisement